Interní Med. 2008; 10(1): 15-18

Oral agents

prof. MUDr. Jindřiška Perušičová DrSc
I. Interní klinika 2. LF UK a FN Motol, Praha

One of the most important changes in the treatment of patients with diabetes mellitus type 2 with oral agents are „New guidelines for DM type 2“, which were prepared of IDF, EASD and ADA. Treatment strategy is changing with emphasis on the early starting of farmacological treatment with metformin as an agent of „first choice“. Besides 5 groups of oral agents we have at present 6. group – gliptines, a representative of a new incretin strategy of treatment type 2 diabetes mellitus. We require besides a hypoglycemic effect of oral agents also other their abilities: longacting and permanent effect, not increasing body weight, minimal side effects and positive influence on cardiovascular risk.

Keywords: oral agents, gliptines

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Perušičová J. Oral agents. Interní Med. 2008;10(1):15-18.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Definition, diagnosis and classification of diabetes mellitus and its complications. World Health Organization, Geneva, 1999.
    2. Goldstein J. Clinical transslation of" a diabetes outcome progression trial" - ADOPT (Approproate Combination Oral Therapies in Type 2 diabetes). J Clin Endocrinol Metab, 2007; 92: 1226-1228. Go to original source... Go to PubMed...
    3. IDF clinical guidelines task force. Global guidelines for type 2 diabetes: recommendation for standard, comprehensive and minimal care. Diabet Med, 2006; 23: 579-593. Go to PubMed...
    4. Johnson JA, Simpson SH, Toth EL, et al. Reduces cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005; 22: 497-505. Go to original source... Go to PubMed...
    5. Johnson JA, Majumdar SR, et al. Decreased mortality associated with the use of metformin compared with sulphonylurea monotherapy in type 2 diabetes. Diabetes Care 2003; 26(1): 243-244.
    6. Nathan DM, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia, 2006; 49: 1711-1721. Go to original source... Go to PubMed...
    7. Pelikánová M. Sulfonylureová perorální antidiabetika, In: Diabetologie 2007, edit: J. Perušičová, Triton Praha 2007: 37-68.
    8. Perušičová J. Metformin-jeho úloha jako perorálního antidiabetika v novém tisíciletí. In: Diabetologie 2006, edit: J. Perušičová, Triton Praha 2006: 11-78.
    9. Perušičová J. Léčba obézních pacientů perorálními antidiabetiky. Medinews 2003; 1: 178-181.
    10. Piťhová P. Thiazolidindiony - rozkvět a soumrak nové skupiny perorálních antidiabetik, In Diabetologie 2007, edit: J. Perušičová, Triton Praha 2007: 37-68.
    11. Rosenberg DE, Jabour SA, Goldstein BJ: Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes Obes Metab 2005; 7: 642-653. Go to original source... Go to PubMed...
    12. Saenz A. Metformin monotherapy for type 2 diabetes. The Cochrane Database of System Rev 2005; 3: CD002966. Go to original source... Go to PubMed...
    13. Salpeter S, Greyber E, Paternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med 2003; 163: 2594-2602. Go to original source... Go to PubMed...
    14. Škrha J, et al. Endothelial function and oxidative stress are changed by metformin in type 2 diabetes. Diabetologia 2005; 48 (Suppl. 1): 278.
    15. UKPDS 28. A randomized trial of efficacy of early addition of metformin in sulphonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92.
    16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998; 352: 854-89-65. Go to original source... Go to PubMed...
    17. Vitale C et al. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005; 258 (3): 250-256. Go to original source... Go to PubMed...
    18. Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. Br J Clin Pharmacol 2002; 53: 549P-550P. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.